General practitioners knowledge about use of topical corticosteroids in paediatric atopic dermatitis in Australia

Aust Fam Physician. 2017;46(5):335-340.

Abstract

Background: Topical corticosteroids are the standard of care in paediatric atopic dermatitis (pAD). However, messages that overstress possible side effects can have a negative impact on perceptions of safety and contribute to treatment non-adherence. The aim of this study was to assess general practitioners' (GPs') perception of the safety of topical corticosteroids in pAD treatment.

Methods: Australian GPs participating in continuing professional development programs were assessed before an education session on pAD. Responses were recorded via an electronic survey.

Results: A total of 257 GPs were surveyed. More than one-third (40.7%) of the GPs instructed parents to apply topical corticosteroids for two weeks or less. Nearly half (47.7%) instructed parents to apply topical corticosteroids sparingly or with the smallest amount possible. Furthermore, nearly one-third (30.2%) reported skin atrophy as the most common side effect of topical corticosteroids.

Discussion: Advice to patients given by Australian GPs may carry unintentional risk messages contributing to treatment non‑adherence. Evidence-based information on the safety of topical corticosteroids is needed to empower GPs to improve treatment outcomes in pAD.

MeSH terms

  • Administration, Topical
  • Adrenal Cortex Hormones / pharmacology
  • Adrenal Cortex Hormones / therapeutic use*
  • Adult
  • Aged
  • Atrophy / etiology
  • Australia
  • Clinical Competence / standards*
  • Clinical Competence / statistics & numerical data
  • Dermatitis, Atopic / complications
  • Dermatitis, Atopic / drug therapy*
  • Dermatologic Agents / pharmacology
  • Dermatologic Agents / therapeutic use
  • Female
  • General Practitioners / standards*
  • General Practitioners / statistics & numerical data
  • Humans
  • Male
  • Middle Aged
  • Pediatrics / methods
  • Surveys and Questionnaires
  • Treatment Outcome
  • Workforce

Substances

  • Adrenal Cortex Hormones
  • Dermatologic Agents